Reyon Pharmaceutical Co Ltd

REYON Pharmaceutical Co., Ltd. manufactures and sells medicines across a wide range of therapeutic areas, including adrenal corticosteroids, angiotensin II receptor antagonists, antibiotics, antihypertensives, anti-inflammatory enzymes, antilipidemic, antirheumatic, and oral hypoglycemic agents, and many others. The company is also developing gene therapies and other drug candidates such as VM202RY for vascular neurological diseases, VM206RY for breast cancer, RY103 [NS101] for Alzheimer's disease, RY104 for age-related macular degeneration, BIO-101 for hepatitis B, RY105 for liver fibrosis, GB102 for chronic kidney and coronary artery disease, RY110 for solid tumors, and RY108, an antifungal drug. Additionally, it researches RY106/RY107 for mRNA-based virus vaccines and rare genetic diseases, and RY109 for ovarian cancer. Founded in 1955, REYON Pharmaceutical is headquartered in Seoul, South Korea.